Tevogen Bio has entered a partnership with BioCentriq, a New Jersey based cell and gene therapy development and manufacturing center, to support clinical manufacturing of Tevogen’s investigational COVID-19 treatment.   Both partners will collaborate at BioCentriq’s state-of-the art GMP facilities to produce Tevogen’s proprietary COVID-19 targeted T cells. The teams will leverage processes and technology required to ensure quality standards are met in the large scale manufacturing of Tevogen’s ...